Research programme: superoxide dismutase mimetics - Galera Therapeutics

Drug Profile

Research programme: superoxide dismutase mimetics - Galera Therapeutics

Alternative Names: Dismutase mimetics - Galera Therapeutics; GC-4711

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Galera Therapeutics
  • Class Small molecules
  • Mechanism of Action Antioxidants; Superoxide dismutase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Fibrosis; Stomatitis

Most Recent Events

  • 19 Jun 2017 Galera Therapeutics plans a phase I trial in Healthy volunteers (IV) (NCT03194139)
  • 10 Apr 2017 Galera Therapeutics plans the phase I GTO-003 trial of GC 4711 in comparision with GC 4419 in Healthy Volunteers in Australia (PO, Capsule) (NCT03099824)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top